These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Intravenous peramivir inhibits viral replication, and leads to bacterial clearance and prevention of mortality during murine bacterial co-infection caused by influenza A(H1N1)pdm09 virus and Streptococcus pneumoniae. Onishi M; Kitano M; Taniguchi K; Homma T; Kobayashi M; Yoshinaga T; Naito A; Sato A Antiviral Res; 2015 May; 117():52-9. PubMed ID: 25752738 [TBL] [Abstract][Full Text] [Related]
27. Antiviral potential of exogenous human omega interferon to inhibit pandemic 2009 A (H1N1) influenza virus. Xu C; Song X; Fu L; Dong D; Wu S; Li G; Yi S; Yu T; Yu R; Hou L; Chen W Viral Immunol; 2011 Oct; 24(5):369-74. PubMed ID: 22004136 [TBL] [Abstract][Full Text] [Related]
28. Anti-influenza virus activity of propolis in vitro and its efficacy against influenza infection in mice. Shimizu T; Hino A; Tsutsumi A; Park YK; Watanabe W; Kurokawa M Antivir Chem Chemother; 2008; 19(1):7-13. PubMed ID: 18610553 [TBL] [Abstract][Full Text] [Related]
29. Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 feeding enhances humoral immune responses, which are suppressed by the antiviral neuraminidase inhibitor oseltamivir in influenza A virus-infected mice. Takahashi E; Sawabuchi T; Kimoto T; Sakai S; Kido H J Dairy Sci; 2019 Nov; 102(11):9559-9569. PubMed ID: 31495632 [TBL] [Abstract][Full Text] [Related]
30. Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1. Renaud C; Kuypers J; Englund JA J Clin Virol; 2011 Oct; 52(2):70-8. PubMed ID: 21684202 [TBL] [Abstract][Full Text] [Related]
31. Comparison of ribavirin and oseltamivir in reducing mortality and lung injury in mice infected with mouse adapted A/California/04/2009 (H1N1). Zarogiannis SG; Noah JW; Jurkuvenaite A; Steele C; Matalon S; Noah DL Life Sci; 2012 Mar; 90(11-12):440-5. PubMed ID: 22269828 [TBL] [Abstract][Full Text] [Related]
32. Pandemic influenza A(H1N1)v viruses currently circulating in New Zealand are sensitive to oseltamivir. Hall RJ; Peacey MP; Ralston JC; Bocacao J; Ziki M; Gunn W; Quirk A; Huang QS Euro Surveill; 2009 Jul; 14(30):19282. PubMed ID: 19643060 [TBL] [Abstract][Full Text] [Related]
33. Postinfection A77-1726 treatment improves cardiopulmonary function in H1N1 influenza-infected mice. Aeffner F; Bratasz A; Flaño E; Powell KA; Davis IC Am J Respir Cell Mol Biol; 2012 Oct; 47(4):543-51. PubMed ID: 22679275 [TBL] [Abstract][Full Text] [Related]
34. The 2009 pandemic H1N1 influenza virus is more pathogenic in pregnant mice than seasonal H1N1 influenza virus. Kim HM; Kang YM; Song BM; Kim HS; Seo SH Viral Immunol; 2012 Oct; 25(5):402-10. PubMed ID: 22985287 [TBL] [Abstract][Full Text] [Related]
35. Novel Ranking System for Identifying Efficacious Anti-Influenza Virus PB2 Inhibitors. Tsai AW; McNeil CF; Leeman JR; Bennett HB; Nti-Addae K; Huang C; Germann UA; Byrn RA; Berlioz-Seux F; Rijnbrand R; Clark MP; Charifson PS; Jones SM Antimicrob Agents Chemother; 2015 Oct; 59(10):6007-16. PubMed ID: 26169418 [TBL] [Abstract][Full Text] [Related]
36. Antiviral activity of a synthesized shikonin ester against influenza A (H1N1) virus and insights into its mechanism. Zhang Y; Han H; Qiu H; Lin H; Yu L; Zhu W; Qi J; Yang R; Pang Y; Wang X; Lu G; Yang Y Biomed Pharmacother; 2017 Sep; 93():636-645. PubMed ID: 28688289 [TBL] [Abstract][Full Text] [Related]
37. Competitive transmissibility and fitness of oseltamivirsensitive and resistant pandemic influenza H1N1 viruses in ferrets. Duan S; Boltz DA; Seiler P; Li J; Bragstad K; Nielsen LP; Webby RJ; Webster RG; Govorkova EA Influenza Other Respir Viruses; 2011 May; 5(Suppl 1):79-82. PubMed ID: 21751461 [No Abstract] [Full Text] [Related]
38. Persistence of pandemic influenza H1N1 virus in young patients after oseltamivir therapy in the 2009-2010 season: a comparison with seasonal H1N1 with or without H275Y mutation. Kawai N; Ikematsu H; Iwaki N; Kondou K; Hirotsu N; Kawashima T; Maeda T; Tanaka O; Doniwa K; Iwakuni O; Egashira K; Yamaji K; Kashiwagi S J Infect Chemother; 2012 Apr; 18(2):180-6. PubMed ID: 22193710 [TBL] [Abstract][Full Text] [Related]
39. Effect of oral gavage treatment with ZnAL42 and other metallo-ion formulations on influenza A H5N1 and H1N1 virus infections in mice. Barnard DL; Wong MH; Bailey K; Day CW; Sidwell RW; Hickok SS; Hall TJ Antivir Chem Chemother; 2007; 18(3):125-32. PubMed ID: 17626596 [TBL] [Abstract][Full Text] [Related]
40. Immunomodulaton and attenuation of lethal influenza A virus infection by oral administration with KIOM-C. Kim EH; Pascua PN; Song MS; Baek YH; Kwon HI; Park SJ; Lim GJ; Kim SM; Decano A; Lee KJ; Cho WK; Ma JY; Choi YK Antiviral Res; 2013 Jun; 98(3):386-93. PubMed ID: 23588232 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]